|Bid||4.1200 x 1300|
|Ask||4.1300 x 1100|
|Day's Range||4.0700 - 4.2800|
|52 Week Range||3.6600 - 11.8200|
|Beta (5Y Monthly)||-1.00|
|PE Ratio (TTM)||4.75|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CODX
An analyst price target cut was the impetus behind Co-Diagnostics' (NASDAQ: CODX) share price drop on Monday. The biotech's stock lost nearly 4% of its value that day; what didn't help was that the cut was preceded by a recommendation downgrade from a different prognosticator. Co-Diagnostics is now worth $9 per share, in the estimation of H.C. Wainwright's Raghuram Selvaraju.
Co-Diagnostics Inc (NASDAQ: CODX) posted Q2 revenue of $5 million, down from $27.4 million a year ago, way below the consensus of $20.5 million, primarily due to lower demand for the Logix Smart COVID-19 Test. The company posted an operating loss of $(4.1) million compared to an operating income of $11.8 million a year ago due to lower sales volumes and continued investments in R&D. Co-Diagnostics recorded an EPS loss of $(0.08), a shift from an EPS income of $0.33, missing the consensus of $0.1
What happened Co-Diagnostics (NASDAQ: CODX), a maker of molecular diagnostics tests, fell 10% on Tuesday. The stock closed at $7.01 a share on Monday, then opened at $6.95 on Wednesday before dropping to a low of $6.